Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/15526
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
Identifiers
ISSN: 1471-2490
WOS ID: 000326648000001
Scopus EID: 2-s2.0-84885795259
PMID: 24144225
Embase PUI: L52828621
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2013-10-21Document type
research articleCitation
Sicras-Mainar A, Rejas J, Navarro-Artieda R, Aguado-Jodar A, Ruiz-Torrejon A, Ibanez-Nolla J, et al. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain. BMC Urol. 2013 Oct 21;13:51.Abstract
Background: Overactive bladder (OAB) is associated with high healthcare costs, which may be partially driven by drug treatment. There is little comparative data on antimuscarinic drugs with respect to resource use and costs. This study was conducted to address this gap and the growing need for naturalistic studies comparing health economics outcomes in adult patients with OAB syndrome initiating treatment with different antimuscarinic drugs in a primary care setting in Spain. Methods: Medical records from the databases of primary healthcare centres in three locations in Spain were assessed retrospectively. Men and women >= 18 years of age who initiated treatment with fesoterodine, tolterodine or solifenacin for OAB between 2008 and 2010 were followed for 52 weeks. Healthcare resource utilization and related costs in the Spanish National Health System were compared. Comparisons among drugs were made using multivariate general linear models adjusted for location, age, sex, time since diagnosis, Charlson comorbidity index, and medication possession ratio. Results: A total of 1,971 medical records of patients (58.3% women; mean age, 70.1 [SD: 10.6] years) initiating treatment with fesoterodine (n = 302), solifenacin (n = 952) or tolterodine (n = 717) were examined. Annual mean cost per patient was (sic)1798 (95% CI: (sic)1745; (sic)1848). Adjusted mean (95% bootstrap CI) healthcare costs were significantly lower in patients receiving fesoterodine ((sic)1639 [1542; 1725]) compared with solifenacin ((sic)1780 [(sic)1699; (sic)1854], P = 0.022) or tolterodine ((sic)1893 [(sic)1815; (sic)1969], P = 0.001). Cost differences occurred because of significantly fewer medical visits, and less use of absorbent products and OAB-related concomitant medication in the fesoterodine group. Conclusions: Compared with solifenacin and tolterodine, fesoterodine was a cost-saving therapy for treatment of OAB in the primary care setting in Spain.
Publisher version
https://dx.doi.org/10.1186/1471-2490-13-51MeSH
CresolsAged
Tolterodine Tartrate
Spain
Benzhydryl Compounds
Humans
Cost-Benefit Analysis
Tetrahydroisoquinolines
Male
Phenylpropanolamine
Urological Agents
Quinuclidines
Female
Treatment Outcome
Cholinergic Agents
Urinary Bladder, Overactive
Primary Health Care
Solifenacin Succinate
Syndrome
Health Care Costs
Prevalence
Retrospective Studies
DeCS
ColinérgicosResultado del Tratamiento
Costos de la Atención en Salud
Tetrahidroisoquinolinas
Prevalencia
Síndrome
Femenino
Succinato de Solifenacina
Análisis Costo-Beneficio
Masculino
Vejiga Urinaria Hiperactiva
Tartrato de Tolterodina
Quinuclidinas
Humanos
Fenilpropanolamina
Agentes Urológicos
Anciano
Compuestos de Bencidrilo
Atención Primaria de Salud
Estudios Retrospectivos
Cresoles
España